Blood-based biomarkers move from research to clinical workflow
Plasma p-tau217 assays are being adopted as a triage step before PET or CSF confirmation in specialty memory clinics.
For two decades, confirming Alzheimer's pathology required either a lumbar puncture or an amyloid PET scan - both expensive, both gated by specialist access. Plasma assays measuring phosphorylated tau (most prominently p-tau217) have changed the calculus. Several commercial tests now report performance comparable to CSF in symptomatic patients, and at a fraction of the cost.
The practical shift inside memory clinics is sequencing. Where previously a clinician ordered PET or CSF as a confirmatory test, plasma is increasingly the first step. Negative results may end the workup; positive results trigger confirmation imaging or CSF where required by payor or treatment-eligibility criteria.
Two things to watch:
- Whether primary care adopts the same sequencing, or whether it remains a specialty-clinic phenomenon.
- How payors treat plasma testing - coverage today is uneven, and out-of-pocket costs vary widely.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
- FDA in vitro diagnostic clearances for plasma Alzheimer's biomarkers
- Plasma p-tau217 assay technical disclosures (Quest, Labcorp, C2N, Roche)
- AAIC plasma biomarker validation and real-world performance studies